{"id":5419,"date":"2019-07-09T13:42:57","date_gmt":"2019-07-09T08:12:57","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5419"},"modified":"2021-07-24T12:57:27","modified_gmt":"2021-07-24T07:27:27","slug":"pharma-market-happenings-for-pfizer-eisai-agamatrix","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-pfizer-eisai-agamatrix","title":{"rendered":"NICE endorsement for Pfizer\u2019s Vizimpro; Eisai, Dundee targets Cancer; Capital raise for AgaMatrix"},"content":{"rendered":"\n

NICE recommends Pfizer\u2019s Vizimpro for treating NSCLC<\/strong><\/h4>\n\n\n\n

Not long ago, Pfizer\u2019s Vizimpro <\/strong>(dacomitinib) a tyrosine kinase inhibitor (TKI), was approved as a first-line monotherapy treatment for adult patients living with locally advanced or metastatic non-small lung cancer <\/a><\/strong>(NSCLC). As evaluated by the American Cancer Society, the non-small lung cancer incidence in the United States in 2018 was found to be 234,030 (121,680 in men and 112,350 in women) new cases with 154,050 deaths. Lately, the UK\u2019s National Institute for Health and Care Excellence (NICE) also approved its use once daily to adults.<\/strong> Earlier, Vizimpro did not get approval from NICE due to its cost-ineffectiveness. However, AstraZeneca has not been so lucky in its endeavours of getting the approval of its EGFR inhibitor Tagrisso (osimertinib) for the same indication from the cost-effectiveness agency. Pfizer\u2019s assurance to give a discount on Vizimpro has convinced NICE to ponder over its initial decision. At present, as per DelveInisght estimates, the non-small lung cancer therapy market<\/a> comprises Afatinib (Gilotrif), Gefitinib (Iressa), Bevacizumab (Avastin), and others as marketed drugs. <\/p>\n\n\n\n

Eisai, Dundee Uni collaborates to fight Cancer <\/strong><\/h4>\n\n\n\n

Japan\u2019s Eisai<\/strong> has collaborated with the University of Dundee <\/strong>in Scotland, the UK regarding research agreement on Proteolysis Targeting Chimeras <\/strong>(PROTACs) 1 toward drug discovery in the oncology area. PROTACs <\/strong>are a new class of drugs that uses the cell\u2019s natural disposal system to get rid of disease-causing proteins. They will help to target those cancer-causing cells which easily escape from present conventional methods of treating cancer. Under the agreement, Eisai will be able to develop, discover and commercialize new potential compounds to treat cancer<\/strong>. Dundee University is exploring its option by entering into a partnership with many other pharma giants to lift the treatment landscape. Earlier this month, Dundee University has also signed a research agreement with Korean based Korean-based Bukwang Pharmaceutical Company to advance Parkinson\u2019s disease<\/a> therapeutic market. <\/strong><\/p>\n\n\n\n

AgaMatrix raises USD 56 M to sell it’s CGM<\/strong><\/h4>\n\n\n\n

AgaMatrix <\/strong>focused on providing diagnostic technologies for Diabetes<\/strong>, has raised USD 56 million<\/strong> to back the new clinical trials for the commercialisation of Continuous Glucose Monitor (<\/strong>CGM), it’s subsidiary WaveForm<\/strong>\u2019s is developing, in Europe and FDA clearance in the USA. The capital raise includes USD 50 million from Perspective advisors and remaining USD 6 million from new and previous investors. The proceeds will also be used in repaying debt and increase production capacity. The company is excited about the positive results of its continuous glucose monitor clinical trials and garnering a significant chunk of Diabetes <\/a>market share. <\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

NICE recommends Pfizer\u2019s Vizimpro for treating NSCLC Not long ago, Pfizer\u2019s Vizimpro (dacomitinib) a tyrosine kinase inhibitor (TKI), was approved as a first-line monotherapy treatment for adult patients living with locally advanced or metastatic non-small lung cancer (NSCLC). As evaluated by the American Cancer Society, the non-small lung cancer incidence in the United States in […]<\/p>\n","protected":false},"author":1,"featured_media":5080,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[812,450,3422],"industry":[17225],"therapeutic_areas":[17229,17240],"class_list":["post-5419","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-diabetes","tag-parkinsons","tag-parkinsons-disease-therapeutic-market","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-endocrinology-and-metabolic-disorders"],"acf":[],"yoast_head":"\nNICE endorsement for Pfizer\u2019s Vizimpro; Eisai, Dundee targets Cancer<\/title>\n<meta name=\"description\" content=\"Pfizer\u2019s Vizimpro (dacomitinib) receives approval of NICE for the treatment of locally advanced or metastatic non-small lung cancer (NSCLC)...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-pfizer-eisai-agamatrix\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NICE endorsement for Pfizer\u2019s Vizimpro; Eisai, Dundee targets Cancer\" \/>\n<meta property=\"og:description\" content=\"Pfizer\u2019s Vizimpro (dacomitinib) receives approval of NICE for the treatment of locally advanced or metastatic non-small lung cancer (NSCLC)...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-pfizer-eisai-agamatrix\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-07-09T08:12:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png\" \/>\n\t<meta property=\"og:image:width\" content=\"647\" \/>\n\t<meta property=\"og:image:height\" content=\"345\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NICE endorsement for Pfizer\u2019s Vizimpro; Eisai, Dundee targets Cancer","description":"Pfizer\u2019s Vizimpro (dacomitinib) receives approval of NICE for the treatment of locally advanced or metastatic non-small lung cancer (NSCLC)...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-pfizer-eisai-agamatrix","og_locale":"en_US","og_type":"article","og_title":"NICE endorsement for Pfizer\u2019s Vizimpro; Eisai, Dundee targets Cancer","og_description":"Pfizer\u2019s Vizimpro (dacomitinib) receives approval of NICE for the treatment of locally advanced or metastatic non-small lung cancer (NSCLC)...","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-pfizer-eisai-agamatrix","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-07-09T08:12:57+00:00","article_modified_time":"2021-07-24T07:27:27+00:00","og_image":[{"width":647,"height":345,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-pfizer-eisai-agamatrix","url":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-pfizer-eisai-agamatrix","name":"NICE endorsement for Pfizer\u2019s Vizimpro; Eisai, Dundee targets Cancer","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-pfizer-eisai-agamatrix#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-pfizer-eisai-agamatrix#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","datePublished":"2019-07-09T08:12:57+00:00","dateModified":"2021-07-24T07:27:27+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Pfizer\u2019s Vizimpro (dacomitinib) receives approval of NICE for the treatment of locally advanced or metastatic non-small lung cancer (NSCLC)...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-pfizer-eisai-agamatrix"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-pfizer-eisai-agamatrix#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","width":647,"height":345,"caption":"Recent Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new-300x160.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Diabetes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s disease therapeutic market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Diabetes<\/span>","<span class=\"advgb-post-tax-term\">Parkinson\u2019s<\/span>","<span class=\"advgb-post-tax-term\">Parkinson\u2019s disease therapeutic market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jul 9, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jul 9, 2019 1:42 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Recent Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5419","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5419"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5419\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5080"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5419"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5419"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}